Skip to main content
. 2011 Jul 12;5:143–154. doi: 10.4137/BCBCR.S7156

Figure 3.

Figure 3

Delphinidin inhibits HER2 and MAPK signaling in breast cancer cells. (A) SKBR3 cells were treated with 50 μg/mL delphinidin for 6, 24, or 48 h. (B) HCC1806 cells were treated with 50 μg/mL delphinidin for 1, 5, 15, or 30 min. Control cells were treated with DMSO at the volume found in this concentration of delphinidin for the longest time point (48 h in (A) or 30 min in (B)). Total protein lysates were immunoblotted for (A) phosphorylated and total HER2, Akt, and Erk1/2, or (B) p-Akt, total Akt, p-Erk1/2, total Erk1/2, p-JNK MAPK, and p-p38 MAPK; actin served as a loading control. (C) MDA468 cells were treated with 50 μg/mL delphinidin for 0.5, 3, 6, or 24 h. Control cells were treated with DMSO at the volume equivalent to that in 50 μg/mL delphinidin for 24 h. Lysates were blotted for phosphorylated and total Akt and Erk1/2; actin served as a loading control.